Ganirelix

Summary

Ganirelix (CHEMBL1251) is an approved protein (ATC H01CC01) targeting GNRHR; indicated across 4 conditions including female infertility and infertility disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H01CC01
• Targets: 1 (GNRHR)
• Indications: 4 conditions
• Clinical trials: 29
• Chemistry: 1570.3 Da · C80H113ClN18O13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1251
Name	Ganirelix
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	16130957
ATC	H01CC01
Molecular formula	C80H113ClN18O13
Molecular weight	1570.3
InChIKey	GJNXBNATEDXMAK-PFLSVRRQSA-N

SMILES: CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC

IUPAC name: (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide

Also known as: Ganirelix, Orgalutran, GANIRELIX

Parent form; salt/anhydrous children: CHEMBL5314377

Patent coverage: 21 distinct patent families (44 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 43 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GNRHR	GnRH1 receptor	Antagonist		0.1%	P30968

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GNRHR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hormone ligand-binding receptors	1	GNRHR
G alpha (q) signalling events	1	GNRHR

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
gonadotropin secretion	1
cellular response to hormone stimulus	1
signal transduction	1
cellular response to gonadotropin-releasing hormone	1

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
female infertility	4	MONDO:0021124	EFO:0008560
infertility disorder	3	MONDO:0005047	EFO:0000545
polycystic ovary syndrome	0	MONDO:0008487	EFO:0000660

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 29.

Phase distribution

Phase	Trials
Not specified	10
PHASE4	8
PHASE3	7
EARLY_PHASE1	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06637189	PHASE4	NOT_YET_RECRUITING	Protocol with Progestin-primed Ovarian Stimulation (PPOS) from the Beginning of Stimulation Versus Protocol with GnRH Antagonists for Ovarian Stimulation in Patients Undergoing DUOSTIM with Embryo Accumulation for PGT-A.
NCT00417183	PHASE4	UNKNOWN	Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation
NCT00461422	PHASE4	COMPLETED	Early Follicular Supplementation of Ganirelix in IVF 2004
NCT00802360	PHASE4	COMPLETED	MENOPUR® Versus FOLLISTIM®
NCT02069808	PHASE4	COMPLETED	Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation
NCT02796105	PHASE4	COMPLETED	Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
NCT04728659	PHASE4	UNKNOWN	Desogestrel Versus GnRH Antagonist in IVF/ICSI
NCT05071339	PHASE4	UNKNOWN	GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth
NCT00696800	PHASE3	COMPLETED	A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)
NCT00725491	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)
NCT00823602	PHASE3	UNKNOWN	Agonist Gonadotropin-Releasing Hormone (GnRH) Versus Antagonist GnRH
NCT01599494	PHASE3	WITHDRAWN	An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
NCT01816321	PHASE3	COMPLETED	Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial
NCT02118051	PHASE3	COMPLETED	Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.
NCT06091436	PHASE3	COMPLETED	To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference
NCT00988260	PHASE2	COMPLETED	Japanese Bridging Trial of Org 37462 (Study P05969)(COMPLETED)
NCT03142893	PHASE1	ACTIVE_NOT_RECRUITING	Hormonal Mechanisms of Sleep Restriction - Axis Study
NCT04037605	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
NCT05751252	EARLY_PHASE1	COMPLETED	Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.
NCT06481696	Not specified	RECRUITING	Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility
NCT00702273	Not specified	COMPLETED	Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)
NCT00703014	Not specified	COMPLETED	Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
NCT00724789	Not specified	COMPLETED	Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)
NCT00780858	Not specified	COMPLETED	Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI
NCT01304511	Not specified	COMPLETED	Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®
NCT01424618	Not specified	UNKNOWN	A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs
NCT01645241	Not specified	COMPLETED	Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
NCT02635607	Not specified	UNKNOWN	Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol
NCT03300518	Not specified	COMPLETED	Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

Molecule	Source	Status	Shared targets
CETRORELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
DEGARELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ELAGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
RELUGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ABARELIX	ChEMBL	Phase 4 (approved)	GNRHR
GONADORELIN	ChEMBL	Phase 4 (approved)	GNRHR
LEUPROLIDE	ChEMBL	Phase 4 (approved)	GNRHR
LINZAGOLIX	ChEMBL	Phase 4 (approved)	GNRHR
ACYLINE	ChEMBL	Phase 2	GNRHR
SUFUGOLIX	ChEMBL	Phase 2	GNRHR
Belzutifan	PubChem	Approved	GNRHR
Deslorelin	PubChem	Approved	GNRHR
Triptorelin	PubChem	Approved	GNRHR